Bone strengthening drugs linked to cancer
Oxford University researchers have found that long-term use of bone strengthening drugs, often used to treat fractures, doubled the risk of oesophageal cancer among 60-79 year olds.
Although the risk was small, from one in 1,000 to two in 1,000, researchers say further research is warranted to determine if benefits outweigh the potential risk.
Findings of the 3,000 person study in the United Kingdom were published in the British Medical Journal.
“Our findings are part of a wider picture. Bisphosphonates are being increasingly prescribed to prevent fracture and what is lacking is reliable information on the benefits and risks of their use in the long term,” said lead researcher, Dr Jane Green.
Anyone taking such drugs is encouraged to discuss any concerns with a doctor.
